Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study.
J Headache Pain
; 24(1): 102, 2023 Aug 03.
Article
in En
| MEDLINE
| ID: mdl-37537578
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Botulinum Toxins, Type A
/
Courage
/
Migraine Disorders
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
J Headache Pain
Journal subject:
MEDICINA INTERNA
/
NEUROLOGIA
/
PSICOFISIOLOGIA
Year:
2023
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom